DTIL - Precision BioSciences, Inc.
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.7670 |
| Open | 0.7800 |
| Bid | 0.7800 x 2200 |
| Ask | 0.8000 x 1800 |
| Day's Range | 0.7490 - 0.7899 |
| 52 Week Range | 0.6820 - 2.2100 |
| Volume | |
| Avg. Volume | 596,738 |
| Market Cap | 85.345M |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.29 |
Fair Value
Related Research
Business WirePrecision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
DURHAM, N.C., May 31, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced program updates across its allogeneic CAR T pipeline. The Company highlighted new interim clinical data for its lead candidate, azercabtagene zapreleucel (azer-cel), as a potential first-in-class allogeneic CD19 CAR T for the growing CAR T relapsed patient population with DLBCL. The Compan
Business WirePrecision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
DURHAM, N.C., May 25, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on May 31, 2023 at 8:30 AM ET.
Business WirePrecision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
DURHAM, N.C., May 24, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will participate in the Stifel Genetic Medicines Day taking place May 30, 2023.
Business WirePrecision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
DURHAM, N.C., May 19, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the company will present preclinical data demonstrating the potential of ARCUS in vivo gene editing for large gene excisions toward the goal of treating Duchenne muscular dystrophy (DMD) at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting. The oral presentation
Business WirePrecision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
DURHAM, N.C., May 12, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that its late-breaking abstract presenting preclinical in vivo gene editing data for its PBGENE-DMD program, being developed for the potential treatment of Duchenne muscular dystrophy (DMD), is available through the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting websi
ZacksPrecision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WirePrecision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
DURHAM, N.C., May 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
Business WirePrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., May 08, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April 27, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan"). The inducement awards consist of
Business WirePrecision BioSciences to Report First Quarter 2023 Results on May 9, 2023
DURHAM, N.C., May 02, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.
Business WirePrecision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
DURHAM, N.C., April 20, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV program. PBGENE-HBV is designed to potentially eliminate hepatitis B virus (HBV) by targeting viral covalently closed circular DNA (cccDNA) in vivo. An abstract relating to the PBGENE-HBV program was selected fo
Business WirePrecision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
DURHAM, N.C., April 19, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking abstract featuring preclinical data from its PBGENE-DMD program for the potential treatment of Duchenne muscular dystrophy (DMD), was selected for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held May 16-20, 2
Simply Wall St.Little Excitement Around Precision BioSciences, Inc.'s (NASDAQ:DTIL) Revenues
With a price-to-sales (or "P/S") ratio of 3.8x Precision BioSciences, Inc. ( NASDAQ:DTIL ) may be sending very bullish...
Business WirePrecision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
DURHAM, N.C., April 13, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/606,856, titled "Engineered meganucleases specific for recognition sequences in the PCSK9 gene." Corresponding international applications in this family have also b
Business WirePrecision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
DURHAM, N.C., March 27, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days taking place April 3-4, 2023.
ZacksPrecision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WirePrecision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.
- Simply Wall St.
A Precision BioSciences, Inc. (NASDAQ:DTIL) insider increased their holdings by 38% last year
Insiders were net buyers of Precision BioSciences, Inc.'s ( NASDAQ:DTIL ) stock during the past year. That is, insiders...
Business WirePrecision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
DURHAM, N.C., March 02, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023.
Business WirePrecision BioSciences Announces Senior Leadership Promotions and Organizational Changes
DURHAM, N.C., February 24, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).
Business WirePrecision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
DURHAM, N.C., February 22, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
- Simply Wall St.
Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week
Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders should be happy to see the share price up 15% in the last...
Business WirePrecision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
DURHAM, N.C., January 09, 2023--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.
Business WirePrecision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
DURHAM, N.C., January 06, 2023--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) provided supportive Type C feedback on the Company’s CMC processes and analytical methods for azercabtagene zapreleucel (azer-cel; PBCAR0191). Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or r
Business WirePrecision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
DURHAM, N.C., December 10, 2022--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today presented a novel, product-attributes analysis of its lead CD19 allogeneic CAR T candidate, Azercabtagene Zapreleucel (azer-cel; PBCAR0191) that shows a relationship between CAR T cell composition and effective cell dose with pharmacokinetics, pharmacodynamics, and clinical outcomes. Data from this
- Simply Wall St.
Precision BioSciences Third Quarter 2022 Earnings: Beats Expectations
Precision BioSciences ( NASDAQ:DTIL ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.36m (down 69% from...